NevusNCT07384299
Impact of Skin Type on Wonud Healing and Scarring Following Facial Skin Surgery
An observational study of Nevus and Seborrheic Keratosis (SK), run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
Trial summary
The goal of this observational study is to learn how an individual's skin type influences the wound healing process and scar formation in Chinese patients undergoing facial dermatologic surgery. Read more about this study
- Who is it for?
- Ages 14 to 60 years
- Conditions the study is for
- Nevus, Seborrheic Keratosis (SK), Cyst
- How many people
- 173 participants
- Where
- 1 siteChina
- Study dates
- 15 Jun 2025to 15 Jan 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 60 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: patients undergoing facial skin surgery to remove benign lesions
Who may be able to join
- Aged between 14 and 60 years.
- Clinically and postoperatively pathologically diagnosed with a facial benign tumor (e.g., melanocytic nevus, sebaceous cyst, seborrheic keratosis, etc.) and having undergone standard surgical treatment.
- Voluntary participation in this study with written informed consent obtained.
- Commitment to comply with all study protocols and to complete all follow-up visits and data collection procedures.
Who cannot join
- Clinically or postoperatively diagnosed with a facial malignant tumor.
- Wounds requiring staged excision or planned for secondary intention healing.
- Surgical site located on or adjacent to the mucosal surface.
- Known history of allergy to any medications or dressings to be used during or after surgery.
- Presence of systemic diseases that significantly impair wound healing (e.g., poorly controlled diabetes, immunodeficiency disorders, active infections).
- Current use of medications affecting wound healing or scar formation (e.g., long-term systemic corticosteroids, immunosuppressants).
Show all 10Show fewer
- Pregnancy or lactation.
- Refusal to provide written informed consent, or anticipated inability to comply with study follow-up and data collection.
- Concurrent participation in another interventional clinical trial.
- Any other condition deemed by the investigator as likely to interfere with study results or increase participant risk.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Baumann Skin Type on Wound Healing and Scar Formation Following Facial Skin Surgery
The goal of this observational study is to learn how an individual's skin type influences the wound healing process and scar formation in Chinese patients undergoing facial dermatologic surgery. The main questions it aims to answer are:
How does skin type affect the quality of wound healing after facial surgery?
Read more
How does skin type affect the formation of hypertrophic scars after facial surgery?
Researchers will compare groups of patients with different skin types (classified by the Baumann Skin Type) to see if there are significant differences in their healing outcomes and scar characteristics.
Participants in this study will:
Receive standard facial dermatologic surgery as part of their clinical care.
Have their skin type assessed preoperatively.
Undergo scheduled postoperative follow-up assessments at 7 and 90 days to evaluate wound healing and scar development using standardized scales.
- Conditions
- Nevus, Seborrheic Keratosis (SK), Cyst, Lipoma, Scar
- Medical subject headings
- Nevus, Keratosis, Seborrheic, Cysts, Lipoma, Cicatrix
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Oily Skin | classified as having oily skin according to the Baumann questionnaire | |
| Dry Skin | classified as having dry skin according to the Baumann questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient and Observer Scar Assessment Scale version 2.0 (POSAS 2.0)
This scale comprises two separate subscales: the Observer Scar Assessment Scale (completed by the clinician) and the Patient Scar Assessment Scale (completed by the participant). The Observer Scale evaluates six items (vascularity, pigmentation, thickness, relief, pliability, and surface area) on a scale from 1 ("like normal skin") to 10 ("the worst scar imaginable"), with a total score ranging from 6 (best) to 60 (worst). The Patient Scale evaluates six items (pain, itching, color, stiffness, thickness, and irregularity) on a scale from 1 ("no, not at all") to 10 ("yes, very much"), with a total score also ranging from 6 (best) to 60 (worst). For both subscales, a higher score indicates a worse scar quality.
Measured: 3-month follow-up
modified Stony Brook Scar Evaluation Scale (mSBSES)
Evaluations were independently performed by two clinicians who were blinded to group allocation. The scale comprises four items: scar width, height, color, and suture marks. Each item is scored from 0 to 2 points, where a score of 2 represents the closest resemblance to normal skin, and 0 represents the worst appearance. The total score ranges from 0 to 8, with a higher score indicating a more ideal scar appearance.
Measured: 3-month follow-up
Secondary outcomes (6)
Incidence of Postoperative Edema
Assessed by direct clinical examination. Unit: % of participants with the presence of edema.
Measured: 7-day follow-up
Incidence of Wound Suppuration
7-day follow-up
Measured: Assessed by direct clinical examination. Unit: % of participants with the presence of suppuration.
Incidence of Peri-wound Erythema
Assessed by direct clinical examination. Unit: % of participants with the presence of erythema.
Measured: 7-day follow-up
Incidence of Wound Tenderness
Assessed by patient report. Unit: % of participants reporting tenderness.
Measured: 7-day follow-up
Incidence of Postoperative Hemorrhage
Assessed by direct clinical examination. Unit: % of participants with active bleeding or hematoma formation.
Measured: 7-day follow-up
Incidence of Peri-wound Ecchymosis
Assessed by direct clinical examination. Unit: % of participants with the presence of ecchymosis.
Measured: 7-day follow-uo
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2026
- Study start15 Jun 2025
- Primary completion15 Jan 2026
- Study completion15 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NevusStudies of the same condition, open and under way.
- More trials run by Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 173 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, YangLiu82, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07384299
- Sponsor's protocol ID
- WuhanUH-2025PFKBaumann
- Status last verified
- Jan 2026
- First submitted
- 18 Jan 2026
- Last updated
- 3 Feb 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Baumann Skin Type on Wound Healing and Scar Formation Following Facial Skin Surgery
- ClinicalTrials.gov ID
- NCT07384299
- Acronym / sponsor ID
- WuhanUH-2025PFKBaumann
- Conditions
- Nevus, Seborrheic Keratosis (SK), Cyst, Lipoma, Scar
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 173 participants (actual)
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUniversity, hospital or other
- Study start
- 15 Jun 2025 (actual)
- Primary completion
- 15 Jan 2026 (actual)
- Study completion
- 15 Jan 2026 (actual)
- First posted
- 3 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn how an individual's skin type influences the wound healing process and scar formation in Chinese patients undergoing facial dermatologic surgery. The main questions it aims to answer are:
How does skin type affect the quality of wound healing after facial surgery?
How does skin type affect the formation of hypertrophic scars after facial surgery?
Researchers will compare groups of patients with different skin types (classified by the Baumann Skin Type) to see if there are significant differences in their healing outcomes and scar characteristics.
Participants in this study will:
Receive standard facial dermatologic surgery as part of their clinical care.
Have their skin type assessed preoperatively.
Undergo scheduled postoperative follow-up assessments at 7 and 90 days to evaluate wound healing and scar development using standardized scales.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Oily Skin | – | –classified as having oily skin according to the Baumann questionnaire |
| Dry Skin | – | –classified as having dry skin according to the Baumann questionnaire |
Who may qualify
- Ages
- 14 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- patients undergoing facial skin surgery to remove benign lesions
Key inclusion criteria (4 listed)
- Aged between 14 and 60 years.
- Clinically and postoperatively pathologically diagnosed with a facial benign tumor (e.g., melanocytic nevus, sebaceous cyst, seborrheic keratosis, etc.) and having undergone standard surgical treatment.
- Voluntary participation in this study with written informed consent obtained.
- Commitment to comply with all study protocols and to complete all follow-up visits and data collection procedures.
Key exclusion criteria (10 listed)
- Clinically or postoperatively diagnosed with a facial malignant tumor.
- Wounds requiring staged excision or planned for secondary intention healing.
- Surgical site located on or adjacent to the mucosal surface.
- Known history of allergy to any medications or dressings to be used during or after surgery.
- Presence of systemic diseases that significantly impair wound healing (e.g., poorly controlled diabetes, immunodeficiency disorders, active infections).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Patient and Observer Scar Assessment Scale version 2.0 (POSAS 2.0)
Time frame: 3-month follow-up
This scale comprises two separate subscales: the Observer Scar Assessment Scale (completed by the clinician) and the Patient Scar Assessment Scale (completed by the participant). The Observer Scale evaluates six items (vascularity, pigmentation, thickness, relief, pliability, and surface area) on a scale from 1 ("like normal skin") to 10 ("the worst scar imaginable"), with a total score ranging from 6 (best) to 60 (worst). The Patient Scale evaluates six items (pain, itching, color, stiffness, thickness, and irregularity) on a scale from 1 ("no, not at all") to 10 ("yes, very much"), with a total score also ranging from 6 (best) to 60 (worst). For both subscales, a higher score indicates a worse scar quality.
modified Stony Brook Scar Evaluation Scale (mSBSES)
Time frame: 3-month follow-up
Evaluations were independently performed by two clinicians who were blinded to group allocation. The scale comprises four items: scar width, height, color, and suture marks. Each item is scored from 0 to 2 points, where a score of 2 represents the closest resemblance to normal skin, and 0 represents the worst appearance. The total score ranges from 0 to 8, with a higher score indicating a more ideal scar appearance.
6 secondary outcomes
Incidence of Postoperative Edema
Time frame: 7-day follow-up
Incidence of Wound Suppuration
Time frame: Assessed by direct clinical examination. Unit: % of participants with the presence of suppuration.
Incidence of Peri-wound Erythema
Time frame: 7-day follow-up
Incidence of Wound Tenderness
Time frame: 7-day follow-up
Incidence of Postoperative Hemorrhage
Time frame: 7-day follow-up
Incidence of Peri-wound Ecchymosis
Time frame: 7-day follow-uo
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2026.
Related trials for Nevus
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Melanoma
Active, not recruitingPhase 1/2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Nevus and Seborrheic Keratosis (SK), run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient and Observer Scar Assessment Scale version 2.0 (POSAS 2.0) (time frame: 3-month follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2026.